The key role of fast toxicology material delivery in biopharma

Investigational New Drug (IND) and Clinical Trial Application (CTA) approvals can help attract additional funding but pre-clinical toxicology studies often present a bottleneck. Alejandro Fernandez-Martell and James Berrie from Lonza argue this can be mitigated through accelerated toxicology material delivery. They claim using Lonza’s offerings, such as the GS piggyBac® system, toxicology material for monoclonal antibodies can be produced within two and a half months post-transfection, reducing potential delays.